Wednesday, October 31, 2012

Avastin receives EU Approval for the treatment of women with recurrent platinum sensitive ovarian cancer

Avastin is the first biologic therapy to be approved for newly diagnosed and recurrent ovarian cancer. It is approved for use in combination with carboplatin and gemcitabine.

Avastin is already approved by the EC as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer.

The additional approval of the medicine is important for women with ovarian cancer who are now able to receive Avastin in combination with chemotherapy once their disease returns. Patients are said to have ‘platinum-sensitive’ disease if their ovarian cancer returns more than 6 months after completion of platinum-based chemotherapy

This approval was based on data from the phase III OCEANS study which showed that women with recurrent, platinum-sensitive ovarian cancer who received Avastin in combination with chemotherapy lived significantly longer without their disease getting worse (progression-free survival) compared to those who received chemotherapy alone (HR=0.48; p<0.0001).

About Ovarian Cancer
Ovarian cancer is the eighth most commonly diagnosed cancer in women and the seventh leading cause of cancer death among women worldwide. Each year, an estimated 230,000 women are diagnosed with ovarian cancer around the world, and approximately 140,000 die from the disease(1). Surgery to remove as much of the tumour as possible is a mainstay of treatment but unfortunately, the majority of patients are diagnosed with late stage disease (when the cancer has grown or spread) and they require further treatment